| 1 |
Soleimanpour S, Yaghoubi A, Sadat Seddighinia F, Rezaee SAR. A century of attempts to develop an effective tuberculosis vaccine: Why they failed? Int Immunopharmacol 2022;109:108791. [PMID: 35487086 DOI: 10.1016/j.intimp.2022.108791] [Reference Citation Analysis]
|
| 2 |
Shahzad M, Anwar S, Qureshi J, Zaman M, Jilani A. DNA vaccine construct formation using Mycobacterium-specific gene Inh-A. J Prev Diagn Treat Strategies Med 2022;1:192. [DOI: 10.4103/jpdtsm.jpdtsm_63_22] [Reference Citation Analysis]
|
| 3 |
Sefidi-heris Y, Jahangiri A, Mokhtarzadeh A, Shahbazi M, Khalili S, Baradaran B, Mosafer J, Baghbanzadeh A, Hejazi M, Hashemzaei M, Hamblin MR, Santos HA. Recent progress in the design of DNA vaccines against tuberculosis. Drug Discovery Today 2020;25:1971-87. [DOI: 10.1016/j.drudis.2020.09.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 4 |
Milani A, Basirnejad M, Bolhassani A. Heat-shock proteins in diagnosis and treatment: an overview of different biochemical and immunological functions. Immunotherapy 2019;11:215-39. [PMID: 30730280 DOI: 10.2217/imt-2018-0105] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 5 |
Somu P, Paul S. Inter-Relationship Between the Inflammation and Heat Shock Protein in Cancer Development: A Possible Target for Diagnosis and Cancer Immunotherapy. Heat Shock Proteins in Human Diseases 2020. [DOI: 10.1007/7515_2020_19] [Reference Citation Analysis]
|
| 6 |
Tripathi P, Batra JK. Heat Shock Proteins in the Pathogenesis of Mycobacterium tuberculosis. Mycobacterium Tuberculosis: Molecular Infection Biology, Pathogenesis, Diagnostics and New Interventions 2019. [DOI: 10.1007/978-981-32-9413-4_13] [Reference Citation Analysis]
|
| 7 |
Romani B, Kavyanifard A, Allahbakhshi E. Antibody production by in vivo RNA transfection. Sci Rep 2017;7:10863. [PMID: 28883620 DOI: 10.1038/s41598-017-11399-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Mascart F, Locht C. Integrating knowledge of Mycobacterium tuberculosis pathogenesis for the design of better vaccines. Expert Review of Vaccines 2015;14:1573-85. [DOI: 10.1586/14760584.2015.1102638] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 9 |
Zhao S, Song X, Zhao Y, Qiu Y, Mao F, Zhang C, Bai B, Zhang H, Wu S, Shi C. Protective and therapeutic effects of the resuscitation-promoting factor domain and its mutants against Mycobacterium tuberculosis in mice. Pathogens and Disease 2015;73. [DOI: 10.1093/femspd/ftu025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 10 |
Gröschel MI, Prabowo SA, Cardona P, Stanford JL, Werf TSVD. Therapeutic vaccines for tuberculosis—A systematic review. Vaccine 2014;32:3162-8. [DOI: 10.1016/j.vaccine.2014.03.047] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 11 |
Mir SA, Verma I, Sharma S. Immunotherapeutic potential of recombinant ESAT-6 protein in mouse model of experimental tuberculosis. Immunol Lett 2014;158:88-94. [PMID: 24345702 DOI: 10.1016/j.imlet.2013.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 12 |
Wang P, Wang L, Zhang W, Bai Y, Kang J, Hao Y, Luo T, Shi C, Xu Z. Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice. Hum Vaccin Immunother 2014;10:150-8. [PMID: 23982126 DOI: 10.4161/hv.26171] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 13 |
Lee LH, Hui CF, Chuang CM, Chen JY. Electrotransfer of the epinecidin-1 gene into skeletal muscle enhances the antibacterial and immunomodulatory functions of a marine fish, grouper (Epinephelus coioides). Fish Shellfish Immunol 2013;35:1359-68. [PMID: 23973381 DOI: 10.1016/j.fsi.2013.07.050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 14 |
Ahn SS, Jeon BY, Park SJ, Choi DH, Ku SH, Cho SN, Sung YC. Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis. Vaccine 2013;31:2884-90. [PMID: 23624092 DOI: 10.1016/j.vaccine.2013.04.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 15 |
Khan KH. DNA vaccines: roles against diseases. Germs. 2013;3:26-35. [PMID: 24432284 DOI: 10.11599/germs.2013.1034] [Cited by in Crossref: 125] [Cited by in F6Publishing: 130] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 16 |
Singh SK, Tripathi DK, Singh PK, Sharma S, Srivastava KK. Protective and survival efficacies of Rv0160c protein in murine model of Mycobacterium tuberculosis. Appl Microbiol Biotechnol 2013;97:5825-37. [PMID: 23104642 DOI: 10.1007/s00253-012-4493-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 17 |
Lowrie DB. Tuberculosis vaccine research in China. Emerg Microbes Infect 2012;1:e7. [PMID: 26038419 DOI: 10.1038/emi.2012.3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
Doherty TM. Immunotherapy for TB. Immunotherapy 2012;4:629-47. [DOI: 10.2217/imt.12.52] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 19 |
Ocampo M, Aristizabal-ramirez D, Rodriguez DM, Munoz M, Curtidor H, Vanegas M, Patarroyo MA, Patarroyo ME. The role of Mycobacterium tuberculosis Rv3166c protein-derived high-activity binding peptides in inhibiting invasion of human cell lines. Protein Engineering Design and Selection 2012;25:235-42. [DOI: 10.1093/protein/gzs011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 20 |
Yuan W, Dong N, Zhang L, Liu J, Lin S, Xiang Z, Qiao H, Tong W, Qin C. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice. Vaccine 2012;30:2490-7. [DOI: 10.1016/j.vaccine.2011.06.029] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
You Q, Jiang C, Kong W, Wu Y. Attempted immunotherapy for Mycobacterium tuberculosis with viral and protein vaccines based on Ag85B-ESAT6 in a mouse model. Acta Microbiol Immunol Hung 2012;59:63-75. [PMID: 22510288 DOI: 10.1556/AMicr.59.2012.1.7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 22 |
Zhao S, Zhao Y, Mao F, Zhang C, Bai B, Zhang H, Shi C, Xu Z. Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice. PLoS One 2012;7:e31908. [PMID: 22363768 DOI: 10.1371/journal.pone.0031908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 23 |
Hanif SN, Al-Attiyah R, Mustafa AS. Cellular immune responses in mice induced by M. tuberculosis PE35-DNA vaccine construct. Scand J Immunol 2011;74:554-60. [PMID: 21812801 DOI: 10.1111/j.1365-3083.2011.02604.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 24 |
Shi C, Shi J, Xu Z. A review of murine models of latent tuberculosis infection. Scand J Infect Dis 2011;43:848-56. [PMID: 21892898 DOI: 10.3109/00365548.2011.603745] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 25 |
Hanif SN, Al-Attiyah R, Mustafa AS. DNA vaccine constructs expressing Mycobacterium tuberculosis-specific genes induce immune responses. Scand J Immunol 2010;72:408-15. [PMID: 21039735 DOI: 10.1111/j.1365-3083.2010.02452.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 26 |
Zhang H, Peng P, Miao S, Zhao Y, Mao F, Wang L, Bai Y, Xu Z, Wei S, Shi C. Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice. Scand J Immunol 2010;72:349-57. [PMID: 20883320 DOI: 10.1111/j.1365-3083.2010.02448.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 27 |
Ingolotti M, Kawalekar O, Shedlock DJ, Muthumani K, Weiner DB. DNA vaccines for targeting bacterial infections. Expert Rev Vaccines 2010;9:747-63. [PMID: 20624048 DOI: 10.1586/erv.10.57] [Cited by in Crossref: 89] [Cited by in F6Publishing: 91] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 28 |
Cifuentes DP, Ocampo M, Curtidor H, Vanegas M, Forero M, Patarroyo ME, Patarroyo MA. Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: potential TB vaccine candidate antigen. BMC Microbiol 2010;10:109. [PMID: 20388213 DOI: 10.1186/1471-2180-10-109] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 29 |
Shi C, Zhang H, Zhang T, Wang X, Bai B, Zhao Y, Zhang C, Xu Z. New Alternative Vaccine Component Against Mycobacterium Tuberculosis - Heat Shock Protein 16.3 or its T-Cell Epitope. Scandinavian Journal of Immunology 2009;70:465-74. [DOI: 10.1111/j.1365-3083.2009.02325.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
|
